Philips demonstrates innovation power, topping European Patent Office Medtech filings in 2024
Philips (NYSE: PHG) has emerged as the leading applicant in medical technology patents at the European Patent Office (EPO) in 2024, filing 594 Medtech patent applications. The company's innovations reached nearly 2 billion people in 2024, progressing toward its 2030 target of 2.5 billion lives improved.
With approximately EUR 1.7 billion invested in R&D (over 9% of sales), Philips launched several key AI-powered innovations in 2024, including:
- New Azurion image-guided therapy system for neurovascular treatment
- FDA-cleared AI tools for cardiovascular ultrasound systems
- Philips Spectral CT 7500 RT for radiation therapy planning
- FDA-approved LumiGuide Navigation Wire for reduced radiation exposure
The company filed 1,231 total European patent applications across various domains, maintaining its position as the Netherlands' top patent applicant. Philips' intellectual property portfolio includes 50,500 patent rights, 30,500 trademarks, and 150,000 design rights.
Philips (NYSE: PHG) è emersa come la principale richiedente di brevetti in tecnologia medica presso l'Ufficio Europeo dei Brevetti (EPO) nel 2024, presentando 594 domande di brevetto Medtech. Le innovazioni dell'azienda hanno raggiunto quasi 2 miliardi di persone nel 2024, progredendo verso l'obiettivo del 2030 di migliorare la vita di 2,5 miliardi di persone.
Con circa 1,7 miliardi di euro investiti in R&D (oltre il 9% delle vendite), Philips ha lanciato diverse innovazioni chiave basate sull'IA nel 2024, tra cui:
- Nuovo sistema di terapia guidata da immagini Azurion per il trattamento neurovascolare
- Strumenti IA approvati dalla FDA per sistemi di ecografia cardiovascolare
- Philips Spectral CT 7500 RT per la pianificazione della terapia radiante
- Filo di navigazione LumiGuide approvato dalla FDA per ridurre l'esposizione alle radiazioni
L'azienda ha presentato 1.231 domande di brevetto europee totali in vari settori, mantenendo la sua posizione come principale richiedente di brevetti nei Paesi Bassi. Il portafoglio di proprietà intellettuale di Philips include 50.500 diritti di brevetto, 30.500 marchi e 150.000 diritti di design.
Philips (NYSE: PHG) se ha consolidado como el principal solicitante de patentes en tecnología médica en la Oficina Europea de Patentes (EPO) en 2024, presentando 594 solicitudes de patentes Medtech. Las innovaciones de la empresa alcanzaron a casi 2 mil millones de personas en 2024, avanzando hacia su objetivo de 2030 de mejorar la vida de 2.5 mil millones de personas.
Con aproximadamente 1.7 mil millones de euros invertidos en I+D (más del 9% de las ventas), Philips lanzó varias innovaciones clave impulsadas por IA en 2024, incluyendo:
- Nuevo sistema de terapia guiada por imágenes Azurion para el tratamiento neurovascular
- Herramientas de IA aprobadas por la FDA para sistemas de ultrasonido cardiovascular
- Philips Spectral CT 7500 RT para la planificación de terapia de radiación
- Guía de navegación LumiGuide aprobada por la FDA para reducir la exposición a la radiación
La empresa presentó un total de 1.231 solicitudes de patentes europeas en varios dominios, manteniendo su posición como el principal solicitante de patentes en los Países Bajos. El portafolio de propiedad intelectual de Philips incluye 50,500 derechos de patente, 30,500 marcas y 150,000 derechos de diseño.
필립스 (NYSE: PHG)는 2024년 유럽 특허청(EPO)에서 의료 기술 특허의 주요 신청자로 부상하여 594개의 메드테크 특허 출원을 했습니다. 이 회사의 혁신은 2024년에 거의 20억 명에게 도달했으며, 2030년까지 25억 명의 삶을 개선하겠다는 목표를 향해 나아가고 있습니다.
약 17억 유로를 R&D에 투자하면서 (매출의 9% 이상), 필립스는 2024년에 여러 주요 AI 기반 혁신을 출시했습니다. 여기에는:
- 신경혈관 치료를 위한 새로운 이미지 유도 치료 시스템 Azurion
- 심혈관 초음파 시스템을 위한 FDA 승인 AI 도구
- 방사선 치료 계획을 위한 Philips Spectral CT 7500 RT
- 방사선 노출을 줄이기 위한 FDA 승인 LumiGuide 내비게이션 와이어
회사는 다양한 분야에서 총 1,231개의 유럽 특허 출원을 했으며, 네덜란드의 주요 특허 신청자로서의 위치를 유지하고 있습니다. 필립스의 지적 재산 포트폴리오에는 50,500개의 특허권, 30,500개의 상표 및 150,000개의 디자인 권리가 포함되어 있습니다.
Philips (NYSE: PHG) s'est imposé comme le principal demandeur de brevets en technologie médicale auprès de l'Office Européen des Brevets (OEB) en 2024, déposant 594 demandes de brevets Medtech. Les innovations de l'entreprise ont touché près de 2 milliards de personnes en 2024, progressant vers son objectif de 2,5 milliards de vies améliorées d'ici 2030.
Avec environ 1,7 milliard d'euros investis en R&D (plus de 9 % des ventes), Philips a lancé plusieurs innovations clés alimentées par l'IA en 2024, notamment :
- Nouveau système de thérapie guidée par l'image Azurion pour le traitement neurovasculaire
- Outils d'IA approuvés par la FDA pour les systèmes d'échographie cardiovasculaire
- Philips Spectral CT 7500 RT pour la planification de la radiothérapie
- Fil de navigation LumiGuide approuvé par la FDA pour réduire l'exposition aux radiations
L'entreprise a déposé un total de 1.231 demandes de brevets européens dans divers domaines, maintenant sa position de principal demandeur de brevets aux Pays-Bas. Le portefeuille de propriété intellectuelle de Philips comprend 50.500 droits de brevet, 30.500 marques et 150.000 droits de design.
Philips (NYSE: PHG) hat sich im Jahr 2024 als führender Antragsteller von Patenten in der Medizintechnologie beim Europäischen Patentamt (EPO) etabliert und 594 Medtech-Patent-Anträge eingereicht. Die Innovationen des Unternehmens erreichten 2024 fast 2 Milliarden Menschen und kommen dem Ziel von 2,5 Milliarden verbesserten Lebensbedingungen bis 2030 näher.
Mit etwa 1,7 Milliarden Euro in F&E investiert (über 9 % des Umsatzes) hat Philips im Jahr 2024 mehrere wichtige KI-gestützte Innovationen eingeführt, darunter:
- Neues Azurion-Bildgeführtes Therapiesystem für die neurovaskuläre Behandlung
- Von der FDA genehmigte KI-Werkzeuge für kardiovaskuläre Ultraschallsysteme
- Philips Spectral CT 7500 RT zur Planung der Strahlentherapie
- Von der FDA genehmigter LumiGuide-Navigationsdraht zur Reduzierung der Strahlenexposition
Das Unternehmen hat insgesamt 1.231 europäische Patentanträge in verschiedenen Bereichen eingereicht und seine Position als führender Patentantragsteller in den Niederlanden behauptet. Das geistige Eigentum von Philips umfasst 50.500 Patentrechte, 30.500 Marken und 150.000 Designrechte.
- Leading position in medical technology patents with 594 applications in 2024
- Strong R&D investment of EUR 1.7 billion (>9% of sales)
- FDA approvals for multiple new AI-powered medical innovations
- Reached nearly 2 billion people with healthcare innovations
- Extensive IP portfolio with 50,500 patent rights
- None.
March 25, 2025
Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that in 2024 it was the leading applicant in the field of medical technology at the European Patent Office (EPO), filing 594 Medtech patent applications. This achievement underscores the company's ongoing dedication to transforming healthcare delivery by integrating informatics and AI to improve workflows, enhance the quality of care, and lower costs of care per patient.
The innovations by Philips, which can boast 134 years of innovation history with its research and development programs around the globe, improved the health and well-being of nearly 2 billion people in 2024, keeping it on track towards its target of 2.5 billion lives improved in 2030.
Roy Jakobs, CEO of Royal Philips said: "For more than 130 years, Philips has been at the forefront of innovations improving people’s lives. The 2024 European patent rankings show how we continue to innovate in the hospital and the home – helping to deliver better care for more people. To continue driving greater impact, we have shifted our innovation closer to customers. We want to help healthcare professionals improve patient care and empower people everywhere to take care of their health and well-being.”
As informatics and AI increasingly create value for healthcare both at the hospital as well as at home, approximately half of the company’s R&D investments are focused on these technologies.
Some of the informatics and AI-powered innovations that Philips launched in 2024 include:
- The new Azurion image-guided therapy system with advanced informatics to enhance minimally invasive diagnosis and treatment of stroke and other neurovascular patients.
- FDA-cleared AI tools integrated into the EPIQ CVx and Affiniti CVx ultrasound system to advance cardiovascular imaging and increase automation and productivity, reinforcing Philips’ #1 global position in cardiovascular ultrasound.
- The new Philips Spectral CT 7500 RT, enabling personalized radiation therapy planning to deliver better care to more cancer patients.
- FDA approval for the LumiGuide Navigation Wire, which uses fiber optic technology to reduce radiation for both patients and physicians during minimally invasive surgery.
In total, Philips contributed 1,231 European patent applications across various domains, the most of any Dutch company and continuing the company’s legacy as one of the top applicants since the EPO started publishing the rankings in 2004.
Further illustrating Philips’ innovation leadership is the company’s recent inclusion in the Clarivate Top 100 Global Innovators 2025, marking the company’s 12th consecutive inclusion in this major assessment of global innovators.
Philips invested approximately EUR 1.7 billion in research and development in 2024 to help drive better care for more people. At more than
For further information, please contact:
Elco van Groningen
Philips Global External Relations
Tel.: +31 6 8103 9584
E-mail: media@philips.com
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2024 sales of EUR 18 billion and employs approximately 67,800 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.
Attachments
- AI-enabled cardiovascular ultrasound platform
- AI-enabled cardiovascular ultrasound platform
- Lumiguide navigation wire
- Azurion
- Azurion with 3d treatment view
- Spectral CT7500 for RT
FAQ
How many medical technology patent applications did Philips (PHG) file with the European Patent Office in 2024?
What percentage of sales did Philips (PHG) invest in R&D during 2024?
What are the key AI-powered innovations Philips (PHG) launched in 2024?
How many people did Philips (PHG) innovations reach in 2024, and what is their 2030 target?
